Lonza teams with hospital to produce CAR-T cells at point-of-care

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/dk_photos)
(Image: Getty/dk_photos)

Related tags: CAR-T, CDMO, Lonza, Middle east, israel, Cell therapy, Cell therapy manufacturing, Personalized medicine

Lonza and Israel-based Sheba Medical collaborate to use the CDMO’s manufacturing platform for point-of-care genetically engineered human CAR-T cell production.

Through the agreement Sheba, the largest hospital in Israel and the Middle East region will be able to bolster its in-house cell manufacturing process to produce human CAR-T cells for applications at point-of-care treatment.

Lonza, a Swiss contract development and manufacturing organization (CDMO), will transfer Sheba’s current open, manual protocols, into Lonza’s closed automated Cocoon platfor

Lonza cassette on cocoon
(Image: Lonza) Cassette on Cocoon


The Cocoon platform was developed by Lonza in a collaboration with Octane Biotech. It is a good manufacturing process (GMP) concept for autologous cell therapy manufacturing.

Use of the manufacturing platform will provide Sheba with the capability to produce cell therapies in a scalable manner at a lower cost.

A spokesperson for Lonza told us that the Cocoon is currently in beta-testing and is now at a stage where the company is looking to test the system at the point of care.

“The goal is to make the Cocoon available to clinics as well as biotech and pharma companies, enabling them to treat more patients and reduce the costs of goods,”​ the spokesperson added.

Dror Harats, deputy director for research and development, director of Clinical Trials at Sheba Medical Center, said in a statement, “With the collaborative potential of this venture, we look forward to jointly leading the next personalized cell-therapy revolution.”

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Import Risks & Clinical Supply Depots

Import Risks & Clinical Supply Depots

Catalent Pharma Solutions | 07-Nov-2018 | Case Study

A sponsor running a clinical trial in Israel arranged to ship their clinical trial product from Europe to a depot in Israel. With the protocol based in...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more